Physician

Abdallahsassine Geara, M.D.

According to 2025 Medicare claims, Abdallahsassine Geara, M.D. (NPI: 1629223045) practices nephrology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Philadelphia, PA. This provider's primary affiliated billing organization is UNIVERSITY OF PENN - MEDICAL GROUP (NPI: 1629181912; TIN: 232743545) and primary practice location at 19104-4208. Geara is affiliated with the Penn Medicine Healthcare Partners, LLC (ACO ID: A5318), participating under the MSSP model.

Geara's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 459 traditional Medicare patients, billed 1,282 HCPCS/CPT codes, and received $78,112 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,555 prescription claims across 257 beneficiaries totaling $709,598 in drug costs, led by Crysvita (Burosumab-Twza). 2017 DME data shows 62 claims. Open Payments data shows 72 records totaling $143,162. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $321,901 to $78,112. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $384,677 and ending at $709,598. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	743	3,983	$321,901
2016	820	3,838	$320,045
2017	648	1,883	$132,925
2018	378	1,298	$125,055
2019	420	1,250	$127,498
2020	393	1,030	$107,771
2021	377	918	$104,461
2022	445	1,012	$103,526
2023	433	919	$75,824
2024	459	1,282	$78,112

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	421	5,334	$384,677
2016	430	5,264	$563,617
2017	354	3,128	$500,809
2018	136	606	$71,244
2019	129	862	$61,524
2020	130	663	$48,430
2021	163	740	$214,156
2022	220	1,151	$459,306
2023	232	1,348	$424,286
2024	257	1,555	$709,598

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	103	$4,699
2016	N/R	36	$2,316
2017	N/R	62	$2,175
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	73	110	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	216	302	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	69	124	$62
90935	Hemodialysis procedure with physician evaluation	41	70	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	258	373	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Crysvita	Burosumab-Twza	11	308	$137,777
Farxiga	Dapagliflozin Propanediol	41	2,490	$44,602
Cinacalcet Hcl	Cinacalcet Hcl	13	390	$28,747
Jardiance	Empagliflozin	14	1,080	$20,421
Mycophenolate Mofetil	Mycophenolate Mofetil	23	1,455	$4,628

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$47,600	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	36	$95,562	Hospital Of The Univ Of Penna
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdallahsassine Geara, M.D.?

Tedicare shows public-source Medicare data for Abdallahsassine Geara, M.D. (NPI 1629223045), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdallahsassine Geara, M.D. have ACO affiliation data?

Abdallahsassine Geara, M.D. is shown with ACO affiliation data for Penn Medicine Healthcare Partners, LLC (MSSP, ACO ID A5318).

What billing organization is linked to Abdallahsassine Geara, M.D.?

Abdallahsassine Geara, M.D. is linked to UNIVERSITY OF PENN - MEDICAL GROUP (billing NPI 1629181912) in the available physician profile data.

Does Abdallahsassine Geara, M.D. have Open Payments data?

Abdallahsassine Geara, M.D. has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.